Atopic dermatitis (AD) is a highly variable skin condition with a wide spectrum of clinical manifestations, fluctuating in severity between periods of flares and remissions. It is a highly prevalent, non-communicable, chronic skin condition, ranking 15th among all non-fatal diseases concerning disability-adjusted life years, and first among all skin diseases, with the main disease burden in children. AD prevalence among children is high (20%). In India and South East Asia, lichenification, and hypo- or hyperpigmentation of the skin are common features in AD patients. It is considered a common and burdensome skin disease with a complex pathogenesis. It becomes visible in early childhood with many patients experiencing the disease onset before the age of five years. In infants, the face, scalp, cheeks, and extensor sides of the arms and legs are mostly affected, but the whole body might be involved in severe cases. People with AD have impaired quality of life (QoL) and experience negative effects like sleep disturbances from itching and scratching, skin pain, psychological distress, social restrictions, time-consuming treatments, and reduced productivity at school or work.